Detection of circulating tumor cells in patients with breast cancer using the conditionally reprogrammed cell culture method and reverse transcription-PCR of hTERT and MAGE A1-6
The present study aimed to verify the efficacy of the conditionally reprogrammed cell (CRC) culture method for the detection of circulating tumor cells (CTCs) in breast cancer. CTCs were isolated from the peripheral blood of patients with breast cancer, and culture of the collected CTCs was performed according to the conditional reprogramming protocol. Total RNA was extracted from cultured CTCs, and the hTERT and MAGE A1-6 genes were amplified using reverse transcription-PCR (RT-PCR). In addition, RNA extraction from another blood sample was performed and the expression of the two genes was analyzed by RT-PCR only. Following CRC culture, grown CTCs were observed in 7 samples (23.3%). The CTC detection rates by RT-PCR for the hTERT and MAGE A1-6 genes in CTCs grown using the CRC culture method were 26.7 and 10.0%, respectively. The positive expression rates for the hTERT and MAGE genes in CTCs assessed by RT-PCR only were 44.1 and 23.5%, respectively. When combining the positive expression rates of RT-PCR only and CRC culture for the hTERT and MAGE A1-6 genes, CTC detection rates increased to 53.3 and 23.3%, respectively. Additionally, when combining the positive expression rates of the two genes by either method, the CTC detection rate was the highest value observed. In conclusion, the present study revealed the potential of CRC culture in the detection of CTCs in breast cancer. Furthermore, a combination of CRC culture and RT-PCR for the hTERT and MAGE A1-6 genes is useful in enhancing the detection rate of CTCs in the blood.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR81 (C-term). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human FKSG80 / GPR81 (C-Terminus). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human FKSG80 / GPR81 (N-Terminus). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human FKSG80 / GPR81 (Extracellular Domain). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-TAS1R2 / GPR71 . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-GPR81 / FKSG80 . This antibody is tested and proven to work in the following applications:
Incidence, clinical course and risk factor for recurrent PCR positivity in discharged COVID-19 patients in Guangzhou, China: A prospective cohort study
The phenomenon of COVID-19 patients tested positive for SARS-CoV-2 after discharge (redetectable as positive, RP) emerged globally. The data of incidence rate and risk factors for RP event and the clinical features of RP patients may provide recommendations for virus containment and cases management for COVID-19. We prospectively collected and analyzed the epidemiological, clinical and virological data from 285 adult patients with COVID-19 and acquired their definite clinical outcome (getting PCR positive or not during post-discharge surveillance). By March 10, 27 (9.5%) discharged patients had tested positive for SARS-CoV-2 in their nasopharyngeal swab after a median duration of 7·0 days (IQR 5·0-8·0). Compared to first admission, RP patients generally had milder clinical symptoms, lower viral load, shorter length of stay and improved pulmonary conditions at readmission (p<0.05). Elder RP patients (≥ 60 years old) were more likely to be symptomatic compared to younger patients (7/8, 87.5% vs. 3/19, 18.8%, p = 0.001) at readmission.
Age, sex, epidemiological history, clinical symptoms and underlying diseases were similar between RP and non-RP patients (p>0.05). A prolonged duration of viral shedding (>10 days) during the first hospitalization [adjusted odds ratio [aOR]: 5.82, 95% confidence interval [CI]: 2.50-13.57 for N gene; aOR: 9.64, 95% CI: 3.91-23.73 for ORF gene] and higher Ct value (ORF) in the third week of the first hospitalization (aOR: 0.69; 95% CI: 0.50-0.95) were associated with RP events. In conclusion, RP events occurred in nearly 10% of COVID-19 patients shortly after the negative tests, were not associated with worsening symptoms and unlikely reflect reinfection. Patients’ lack of efficiency in virus clearance was a risk factor for RP result. It is noteworthy that elder RP patients (≥ 60 years old) were more susceptible to clinical symptoms at readmission.
Ovine Paratuberculosis: Seroprevalence and comparison of fecal culture and direct fecal PCR assay
Johne’s disease is chronic, incurable disease, caused by Mycobacterium avium subsp. paratuberculosis (MAP). Most studies in Egypt focused on incidence of the disease in cattle but few studies were reported presence of antibodies against MAP in sheep. The present study determined the seroprevalence rate of MAP among sheep in four Governorates and assessed the associated risk factors to MAP-infection. The seroprevalence rate of MAP among sheep was non-significant varied between different Governorates, it was ranged between 3.75%-12.3%. The results revealed that the seroprevalence rate of the disease was significantly increased in diarrheic sheep (11 %, 95 %CI: 7.2-16.2) during spring (15 %, 95 %CI: 8.3-25) and summer (8%, 95 %CI: 4.13-13.8) seasons. Contrary, the age of sheep and contact with other ruminants like cattle or goats had non-significant effect of spreading of MAP-infection among sheep. The detection of MAP in feces of sheep was carried out using culture and PCR to determine the efficiency of both tests. The kappa test revealed good agreement between both tests for detection of MAP. The obtained finding confirms the presence of MAP among sheep in Egypt. So, the appropriate control measures should be taken to reduce spreading of the disease among sheep and reduce its economic losses.
Description: A polyclonal antibody for detection of GPR12 from Human. This GPR12 antibody is for WB, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human GPR12 at AA rangle: 10-90
Description: A polyclonal antibody for detection of GPR12 from Human. This GPR12 antibody is for WB, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human GPR12 at AA rangle: 10-90
Description: A polyclonal antibody for detection of GPR12 from Human. This GPR12 antibody is for WB, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human GPR12 at AA rangle: 10-90
Description: A polyclonal antibody against GPR12. Recognizes GPR12 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against GPR12. Recognizes GPR12 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against GPR12. Recognizes GPR12 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR12 (N-Terminus). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR12 (Extracellular Domain). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR12 - C-terminal region. This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-TAS1R2 / GPR71 . This antibody is tested and proven to work in the following applications:
